

FORM PTO-1590  
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

78104.023

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/806955

INTERNATIONAL APPLICATION NO.  
PCT/GB99/03316INTERNATIONAL FILING DATE  
08 October 1999PRIORITY DATE CLAIMED  
09 October 1998TITLE OF INVENTION  
TREATMENT OF INFLAMMATORY DISEASEAPPLICANT(S) FOR DO/EO/US  
PANAYI, Gabriel S. et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (unsigned)
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

U.S. APPLICATION NO. (If known to USPTO) <b>09/808955</b>	INTERNATIONAL APPLICATION NO. <b>PCT/GB99/03316</b>	ATTORNEY'S DOCKET NUMBER <b>78104.023</b>
--	--	--

<p>21. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p><b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b></p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$1000.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$860.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$710.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$690.00</b></p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b></p> <p style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></p> <p>Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 20%;">CLAIMS</th> <th style="width: 20%;">NUMBER FILED</th> <th style="width: 20%;">NUMBER EXTRA</th> <th style="width: 20%;">RATE</th> <th style="width: 20%;">\$</th> </tr> <tr> <td>Total claims</td> <td>36 - 20 =</td> <td>16</td> <td>x \$18.00</td> <td>\$ 288.00</td> </tr> <tr> <td>Independent claims</td> <td>9 - 3 =</td> <td>6</td> <td>x \$80.00</td> <td>\$ 480.00</td> </tr> </table> <p>MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270.00 \$ -0-</p> <p style="text-align: right;"><b>TOTAL OF ABOVE CALCULATIONS =</b> \$1,758.00</p> <p><input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. \$ -0-</p> <p style="text-align: right;"><b>SUBTOTAL =</b> \$1,758.00</p> <p>Processing fee of <b>\$130.00</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 \$ -0-</p> <p style="text-align: right;"><b>TOTAL NATIONAL FEE =</b> \$1,758.00</p> <p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + \$ -0-</p> <p style="text-align: right;"><b>TOTAL FEES ENCLOSED =</b> \$1,758.00</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;"><b>Amount to be refunded:</b></td> <td style="width: 40%;">\$</td> </tr> <tr> <td><b>charged:</b></td> <td>\$</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	36 - 20 =	16	x \$18.00	\$ 288.00	Independent claims	9 - 3 =	6	x \$80.00	\$ 480.00	<b>Amount to be refunded:</b>	\$	<b>charged:</b>	\$	<p style="text-align: center;"><b>CALCULATIONS PTO USE ONLY</b></p>
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																
Total claims	36 - 20 =	16	x \$18.00	\$ 288.00																
Independent claims	9 - 3 =	6	x \$80.00	\$ 480.00																
<b>Amount to be refunded:</b>	\$																			
<b>charged:</b>	\$																			

a. ☒ A check in the amount of \$1,758.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 18-2055. A duplicate copy of this sheet is enclosed.


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

DeWitt Ross & Stevens S.C.  
 8000 Excelsior Drive  
 Madison, WI 53717-1914  
 Phone: (608) 831-2100  
 Fax: (608) 831-2106

  
 SIGNATURE: \_\_\_\_\_  
 Joseph T. Leone  
 NAME: \_\_\_\_\_  
 37,170  
 REGISTRATION NUMBER: \_\_\_\_\_

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

International Appln. Serial No.: PCT/GB 99/03316

International Filing Date: 8 October 1999

Applicants: Panayi et al.

Attorney Docket No.: 78104.023

Title: **TREATMENT OF INFLAMMATORY DISEASE**

**PRELIMINARY AMENDMENT, 37 CFR §1.115**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In advance of prosecution on the merits, Applicants respectfully request entry of the following preliminary amendment.

**IN THE CLAIMS**

Please cancel Claims 1-17, without prejudice on the merits to further prosecution of these claims in one or more continuing applications.

Please add new Claims 18-53, as follows:

-- 18. Recombinant immunoglobulin heavy chain binding protein.

19. The recombinant immunoglobulin heavy chain binding protein of Claim 18, having an amino acid sequence as shown in SEQ. ID. NO: 1 or SEQ. ID. NO: 2.
20. An isolated DNA molecule having or containing a nucleotide sequence as shown in SEQ. ID. NO: 3.
21. A recombinant vector comprising a DNA sequence as shown in SEQ. ID. NO: 3.
22. A pharmaceutical composition for the treatment of inflammation in mammals, including humans, the composition comprising an anti-inflammatory-effective amount of immunoglobulin heavy chain binding protein or a peptide derived therefrom, in combination with a pharmaceutically-suitable carrier.
23. The pharmaceutical composition of Claim 22, wherein the immunoglobulin heavy chain binding protein is recombinant immunoglobulin heavy chain binding protein.
24. The pharmaceutical composition of Claim 22, wherein the immunoglobulin heavy chain binding protein has an amino acid sequence as shown in SEQ. ID. NO: 1 or SEQ. ID. NO: 2.
25. The pharmaceutical composition of Claim 22, which is a composition for the treatment of rheumatoid arthritis.

26. A pharmaceutical composition for the treatment of inflammation in mammals, including humans, the composition comprising an anti-inflammatory-effective amount of a DNA encoding immunoglobulin heavy chain binding protein or an anti-inflammatory fragment derived therefrom, in combination with a pharmaceutically-suitable carrier.
27. The pharmaceutical composition of Claim 26, wherein the DNA encoding immunoglobulin heavy chain binding protein is recombinant DNA.
28. The pharmaceutical composition of Claim 26, wherein the DNA encoding immunoglobulin heavy chain binding protein has a nucleotide sequence as shown in SEQ. ID. NO: 3.
29. The pharmaceutical composition of Claim 26, which is a composition for the treatment of rheumatoid arthritis.
30. A method for treating inflammation in a mammalian subject in need thereof, including a human subject, the method comprising administering to the subject an amount of immunoglobulin heavy chain binding protein or a peptide derived therefrom, the amount being effective to ameliorate inflammation in the subject.
31. The method of Claim 30, which is a method of treating rheumatoid arthritis.
32. The method of Claim 30, wherein recombinant immunoglobulin heavy chain binding protein is administered to the subject.

33. The method of Claim 32, wherein recombinant immunoglobulin heavy chain binding protein having an amino acid sequence as shown in SEQ. ID. NO: 1 or SEQ. ID NO: 2 is administered to the subject.
34. The method of Claim 30, wherein the immunoglobulin heavy chain binding protein is administered orally, nasally, subcutaneously, or intravenously.
35. A method for treating inflammation in a mammalian subject in need thereof, including a human subject, the method comprising administering to the subject an amount of a DNA encoding immunoglobulin heavy chain binding protein or a fragment thereof, the amount being effective to ameliorate inflammation in the subject.
36. The method of Claim 35, which is a method of treating rheumatoid arthritis.
37. The method of Claim 35, wherein recombinant DNA encoding immunoglobulin heavy chain binding protein is administered to the subject.
38. The method of Claim 37, wherein recombinant DNA having a nucleotide sequence as shown in SEQ. ID. NO: 3 is administered to the subject.
39. The method of Claim 35, wherein the DNA is administered orally, nasally, subcutaneously, or intravenously.

40. A method for diagnosing the presence of rheumatoid arthritis in a mammalian subject, including a human subject, the method comprising contacting a bodily fluid from the subject selected from the group consisting of whole blood, blood plasma, blood serum, saliva, mucus, synovial fluid, and cerebrospinal fluid, to immunoglobulin heavy chain binding protein or a peptide derived therefrom, and then ascertaining the presence or absence of anti-immunoglobulin heavy chain binding protein antibodies in the bodily fluid tested, the presence of antibodies indicating the presence of rheumatoid arthritis in the subject.
41. The method of Claim 40, wherein the bodily fluid is contacted with recombinant immunoglobulin heavy chain binding protein
42. The method of Claim 40, wherein the bodily fluid is contacted with Immunoglobulin heavy chain binding protein having an amino acid sequence as shown in SEQ. ID. NO: 1 or SEQ. ID. NO: 2.
43. The method of Claim 40, wherein the presence of anti-immunoglobulin heavy chain binding protein antibodies is ascertained using an enzyme-linked immunosorbent assay (ELISA) incorporating immunoglobulin heavy chain binding protein or a peptide derived therefrom.
44. A kit for diagnosing the presence of rheumatoid arthritis in a mammalian subject, including a human subject, the kit comprising:
  - an amount of immunoglobulin heavy chain binding protein
  - or a peptide derived therefrom, disposed in a suitable container.
45. The kit of Claim 44, further comprising instructions for use of the kit.

46. The kit of Claim 44, comprising recombinant immunoglobulin heavy chain binding protein or a peptide derived therefrom.
47. The kit of Claim 44, comprising immunoglobulin heavy chain binding protein having an amino acid sequence as shown in SEQ. ID. NO: 1 or SEQ. ID. NO: 2.
48. The kit of Claim 44, comprising an enzyme-linked immunosorbent assay that incorporates immunoglobulin heavy chain binding protein or a peptide derived therefrom.
49. The kit of Claim 48, comprising recombinant immunoglobulin heavy chain binding protein or a peptide derived therefrom.
50. The kit of Claim 48, comprising SEQ. ID. NO: 1 or SEQ. ID. NO: 2.
51. The kit of Claim 44, comprising a Western Blot assay that incorporates immunoglobulin heavy chain binding protein or a peptide derived therefrom.
52. The kit of Claim 51, comprising recombinant immunoglobulin heavy chain binding protein or a peptide derived therefrom.
53. The kit of Claim 51, comprising SEQ. ID. NO: 1 or SEQ. ID. NO: 2.--




09/806955

JCOB Rec'd PCT/PTO 06 APR 2001

CONCLUSION

The application is now ready for examination on the merits. Early notification of such action is earnestly solicited.

Respectfully submitted,



**Joseph T. Leone, Reg. No. 37,170**  
**DEWITT ROSS & STEVENS S.C.**  
FirstStar Financial Centre  
8000 Excelsior Drive, Suite 401  
Madison, Wisconsin 53717-1914  
Telephone: (608) 831-2100  
Facsimile: (608) 831-2106

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail - Post Office to Addressee, in an envelope addressed to:

**BOX PCT**  
**Assistant Commissioner for Patents,**  
**Washington, D.C. 20231.**

Express Mail Label No. EL800009491 US

Date of Deposit: 06 April 2001

Signature: S. J. D. [Signature]

TREATMENT OF INFLAMMATORY DISEASE

This invention relates to inflammatory disease and more particularly to rheumatoid arthritis.

Rheumatoid arthritis (RA) is a chronic inflammatory disease of the synovial joints which leads to joint destruction, disability and early death. Although the cause of RA is presently unknown, it has been suggested that type II collagen, uniquely found in the articular cartilage, is a possible autoantigen for RA. It has recently been proposed that gp39, a 39KD glycoprotein, and peptides derived from it, are such autoantigens. However, the data supporting this hypothesis are limited and the role of gp39 therefore remains uncertain.

The present invention stems from a different approach based on a study of chondrocytes, the specialised cells of articular cartilage. We have isolated a protein from human chondrocytes and human chondrosarcoma cell lines which reacts with antibodies present in RA patients' sera and meets the accepted criteria for a putative autoantigen. This purified protein has been tested for proliferation of T cells and has been shown to selectively proliferate synovial T cells from patients with RA. This protein is the immunoglobulin heavy chain binding protein BiP(78KD).

International patent application WO 99/18131 proposes the detection of antibodies to a BiP deriving from Hela cells as a diagnostic indication of RA. However, this prior disclosure does not describe the extraction of BiP from the Hela cells in a reproducible manner and is therefore insufficient for practical application.

We have now obtained and identified the correct RA autoantigen and this discovery leads to the development of prognostic and diagnostic tests for this disease and specific therapy. We have isolated and sequenced the DNA for this protein. We have also cloned and expressed this DNA. The amino acid and DNA sequences are novel and are shown in Sequence Listings appended to this specification. The amino acid sequences of the BiP protein are given as sequence listings in two versions SE1 and SE2 either of which may be used as a test reagent in accordance with the present invention. The cDNA for SE1 is given as Sequence listing SE3. This sequence has been deposited with GENBANK under Accession No AF 188611.

A comparison of this sequence with that of GENBANK Accession No X87949 is provided hereinafter.

The first part of the following description concerns the characterisation of such an autoantigen; the second the cloning, sequencing and expression of the protein; and the third part the demonstration of disease (rheumatoid arthritis) and tissue (synovial compartment) T cell specificity to the autoantigen.

### Part 1: CHARACTERISATION OF AUTOANTIGEN

#### Chondrocytes/chondrosarcoma cells.

Chondrocytes were isolated from cartilage obtained during joint replacement. The cartilage was minced finely and digested with 1mg/ml collagenase (Worthington). Following digestion the cells were centrifuged at 300g and resuspended in Dulbeccos minimal essential medium (DMEM)(Life Technologies, Paisley, UK) enriched with 10% foetal calf serum (FCS)(Harlan Sera-Lab, Loughborough, UK). Cell debris was washed off the adherent cells after 24hours and the cells allowed to expand until confluent. Cells were passaged using trypsin (0.25%) and split 1:3.

Chondrosarcoma cells (HTB94) (SW1353) were supplied by the American Type Culture Collection ATCC (Rockville, Maryland, USA) and by Dr J Block, Rush University, Chicago, USA (personal gift). These cells were cultured in DMEM with 10% FCS and split 1:3 after gentle trypsinisation (0.25% trypsin Life Technologies, Paisley, UK) when confluent.

#### Preparation of cell lysates.

Cells were scraped from the flask surface, homogenised and sonicated in the presence of proteinase inhibitors PMSF (2mM), leupeptin (200µg/ml) and aprotinin (50µg/ml) (Sigma, Poole, UK).

Sodium dodecyl sulphate (SDS) (Sigma, Poole, UK) was added to a final concentration of 1% and the proteins solubilised at room temperature for

1 hour. Protein concentration was estimated by bicinchoninic acid assay using bovine serum albumin (BSA) as a standard protein (Sigma) and the cell lysate was used at 10µg/well equivalent.

#### Polyacrylamide gel electrophoresis (PAGE) and Western Blot.

The Mini Protean system (BioRad Laboratories, Hemel Hempstead, UK) was used to run the gels. 5, 7.5 or 10% SDS polyacrylamide denaturing gels 1.5mm thick were prepared (See Appendix 1). Gels were loaded with 10µg protein/well or the equivalent was loaded on preparative gels. Electrophoresis was carried out at a constant 100V and broad range kaleidoscope markers (BioRad) were run in parallel with the cell lysates.

Following electrophoresis the proteins were blotted onto nitrocellulose at a constant 100V for 1 hour (See Appendix 1). Nitrocellulose was then blocked with 3%BSA (Sigma, Poole, UK) and left at 4<sup>0</sup> C overnight. Preparative gel membranes were cut into 16 thin strips when necessary, each having an identical protein profile. The membranes were probed with patients sera (1/100 dilution) or specific monoclonal antibodies (at required concentrations) for 1 hour at room temperature and then washed x3 over 1 hour in TTBS (See Appendix 1). The secondary antibody, goat anti-human IgG (Fab<sup>2</sup>) horse radish peroxidase(HRP) conjugate (Sigma) was added at 1/1000 dilution and incubated for 1 hour at room temperature. The membranes were then washed x3 over 1 hour in TTBS. Enhanced chemiluminescence (Amersham) was used to develop the system and antigen-antibody.HRP complexes appeared as discrete bands on photographic film when developed.

Isolation of the putative autoantigen p78

The band of interest was seen in approximately 30% of the rheumatoid arthritis sera used to screen the cell lysates as previously described.

To isolate the protein the cell lysate was concentrated x 23, using a 30,000MW cut-off filter (Vivascience). This protein was then loaded on 5% and 7.5% gels in parallel. One lane on each was loaded at normal concentration while the two other lanes were overloaded with the protein. Kaleidoscope markers were loaded on either side of the test lanes. The gels were then run as previously described until the kaleidoscope markers showed that the 70,000 MW protein would be in the bottom third of the gel as close as possible to the run-off point. The gels were then blotted onto PVDF membrane (Immobilon P, Millipore) which was immediately placed in distilled water after transfer of the proteins was complete. The strip with normal loading was used for immunodetection of the protein band. The developed film of this immunodetection and Ponceau red staining of the overloaded strips was used to identify the band on the membrane which was then air-dried.

These strips were then taken to isolate and sequence the protein using matrix assisted laser desorption ionisation (MALDI) spectroscopy.

The electroblotted proteins were stained with Ponceau S (0.05% w/v aqueous methanol/0.1% acetic acid) using a rapid-staining protocol (1). The dried, stained proteins were then digested in situ with trypsin (Boehringer, modified) and the peptides extracted with 1:1 v/v formic acid:ethanol (2). One 0.2 µl aliquot (approximately 5% of the total digest) was sampled and directly analysed by matrix-assisted laser desorption ionisation (MALDI) time-of-flight

mass spectrometry using a LaserMat 2000 mass spectrometer (Thermo Bioanalysis, UK) (3). A second 0.2 µl aliquot was quantitatively esterified using 1% v/v thionyl chloride in methanol and also analysed by MALDI to provide acidic residue composition (4). Native and esterified peptide masses were then screened against the MOWSE peptide mass fingerprint database (5). The remaining digested peptides (90% of total digest) were then reacted with N-succinimidyl-2(3-pyridyl) acetate (SPA) in order to enhance b-ion abundance and facilitate sequence analysis by tandem mass spectrometry (6). Dried peptide fractions were treated with 7 µl 1% w/v N-succinimidyl-2(3-pyridyl) acetate in 0.5M HEPES (pH 7.8 with NaOH) containing 15% v/v acetonitrile for 20 min on ice. The reaction was terminated by 1 µl heptafluorobutyric acid (HFBA) and the solution immediately injected onto a capillary reverse-phase column (300 µm x 15cm) packed with POROS R2/H material (Perseptive Biosystems, MA) equilibrated with 2% v/v acetonitrile/0.05% v/v TFA running at 3 µl/min. The absorbed peptides were washed isocratically with 10% v/v acetonitrile/0.05% v/v TFA for 30 minutes at 3 µl/min to elute the excess reagent and HEPES buffer. The derivatised peptides were then eluted with a single step gradient to 75% v/v acetonitrile/0.1% v/v formic acid and collected in a single 4 µl fraction. The derivatised peptides were then sequenced by low-energy collision-activated dissociation (CAD) using a Finnigan MAT TSQ7000 fitted with a nanoelectrospray source (7,8). CAD was performed using 2.5 mTorr argon with collisional offset voltages between -18V and -28V. The product-ion spectra were collected with Q3 scanned at 500 amu/sec.

## RESULTS:

Sequence data obtained from 7.5% gel (single band)

from GR78\_human

Specific identifying peptides:

NQLTSNPENTVFDAK 82-96

SDIDEIVLVGGSTR 353-366

TWNDPSVQQDIK 107-113

Identified human protein GR 78:

Kd glucose related protein precursor (GRP78)

Immunoglobulin heavy chain binding protein (BIP)

Part 2: CLONING, SEQUENCING AND EXPRESSION OF p78

1) mRNA isolation and PCR amplification of identified genes.

Human chondrocytes were isolated and cultured for three weeks as described. Poly(A) mRNA (1-2  $\mu$ g) was extracted with a Micro-Fastrack kit (Invitrogen) from a total of  $1-2 \times 10^6$  cells. One microgram of the resulting mRNA was reverse transcribed into cDNA in a 20  $\mu$ l volume at 45°C for 1 hour using 1  $\mu$ l of Moloney murine leukemia virus reverse transcriptase (200u/ $\mu$ l); 5 X first strand buffer (Tris-HCl pH 8.3, 250mM; KCl 375 mM; MgCl 15mM); 0.1M



DTT; oligo dT(12-18) 20ng/ $\mu$ l (Life Technologies); and dNTP mix 100mM (Amersham Pharmacia Biotech, Uppsala Sweden).

PCR was performed in a 50 $\mu$ l reaction volume under standard conditions (see below) using a Perkin Elmer Applied Biosystems thermal cycler PE2400. Primer sequences were derived from the GenBank database sequence corresponding to the Human gene for the immunoglobulin heavy chain binding protein, Bip (grp78), accession number X87949. Specific primers were synthesized to amplify the putative autoantigen gene from the chondrocyte cDNA. The resulting PCR product consisted of most of the grp78 coding region, bar the untranslated regions, signal sequences and the stop codon (nucleotide positions 279-2169 of the grp78 database sequence).

Primer sets for PCR were designed with integrated restriction sites to allow rapid subcloning of cDNA into the bacterial expression vector. The Forward primers encoded an NdeI site and the Reverse primers contained an XhoI restriction site: The Sequence Listing for the forward primer is given hereafter as SE4 and that for the reverse primer is given as SE5.

Bip Forward primer 5' TATACATATGGAGGAGGACAAGAAGGAGGACG  
3' (32mer)

Bip Reverse primer 5' CCACCTCGAGTTCTGCTGTATCCTCTTCACCA  
3' (32mer)

After initial denaturation at 96°C for 2min the, PCR was performed for 28 cycles using a cycling profile of 94°C for 30s, 60°C for 30s and 72°C for 2min,

with a final extension at 72°C for 7min. The PCR reaction generated a single specific Bip fragment of 1890bp.

### 2) Cloning of PCR generated fragments.

The restriction sites engineered into the forward and reverse primers used for the PCR reactions required flanking DNA for them to be recognised by their specific endonucleases (NdeI and XhoI). To provide this flanking DNA, the PCR generated fragment was cloned into a PCR cloning vector pCR2.1-TOPO (Invitrogen). The ligated plasmids were transformed into competent *E.coli* XL1-Blue (Stratagene) and plasmid DNA extracted using miniprep purification columns (Qiagen). The purified plasmid DNA for the clone was designated Bip-Topo. These DNA samples were stored at -20°C. The purified plasmid DNA for Bip-Topo was digested with NdeI and XhoI. The restricted fragments were separated by agarose gel electrophoresis and purified using the Qiagen DNA gel extraction kit.

### 3) Subcloning of restricted gene fragments into bacterial expression vector.

The purified fragment for the clone was ligated into the NdeI /XhoI pre-digested bacterial expression vector pET30a (Novagen). Ligation was performed at 12°C overnight in the presence of T4 ligase (20 units) and 1/10 vol of 10X ligase buffer (provided with the T4 ligase enzyme from Promega). The ligated plasmids were transformed into competent *E.coli* XL1-Blue (Stratagene) and screened by colony-PCR using Bip specific primers. Positive transformants carrying the required recombinant plasmids were purified and transformed into competent *E.coli* expression strain BL21-(DE3) (Invitrogen).

It will of course be understood that cloning may be carried out in prokaryotic or eukaryotic hosts including bacteria, insect cells, and mammalian cells. Preferred hosts are those which ensure glycosylation of the expressed product.

#### 4) Sequencing of the 1890bp pET30::Bip subclone .

Sequencing of the 5' and 3' terminal ends of the pET30a::Bip clone confirmed that the recombinant DNA molecule was in-frame with the ATG start codon on the pET30 vector and that readthrough from this site continued through the Bip gene and ended with the 6X His residues and the stop codon located on the 3' arm of the expression vector.

Extensive DNA sequencing was performed using synthetic oligonucleotide primers spanning the entire length of the Bip subclone. Sequence analysis of the newly subcloned Bip gene fragment was performed by comparative alignment against the existing grp78 sequence from the database (accession number X87949). A number of differences between the two sequences were detected, both at the DNA and protein level (see Appendix 2). These areas of disagreement may either be a result of errors in the original DNA sequencing (of grp78) or they may indicate the presence of an additional related, but slightly different Bip gene in the genome.

All DNA sequencing was performed on an Applied Biosystems ABI 377 automated DNA sequencer using the dRhodamine dye terminator kit (Perkin Elmer- Applied Biosystems).

Expression of bacterial and purification recombinant proteins.

E.coli expression strain BL21-(DE3) containing the recombinant pET30a-Bip plasmid was grown at 37°C in LB medium containing kanamycin (50µg/ml). When the cells had reached an OD<sub>600</sub> of 0.6units, isopropyl β-D-thiogalactopyranoside (IPTG) (1mM) was added to the medium to induce expression of the recombinant protein, driven by the IPTG-inducible promoter of the expression vector. To allow for maximal expression of the recombinant protein the culture was incubated for a further 4 hours at 37°C. The cells were pelleted by centrifugation and stored at -70°C.

For purification of the recombinant bacterial proteins the bacterial pellets were lysed in binding buffer (20mM NaPO<sub>4</sub>, 500mM NaCl, 5mM Imidazole, 1mM PMSF, 1mg/ml Lysozyme, 5units/ml DNase, 0.1% Triton X-100, pH7.4). The lysate was cleared by centrifugation to remove insoluble matter and cell debris. The cleared lysate was passed over a binding buffer-equilibrated chelating Hi-trap affinity column, with a bed volume of 5ml (Pharmacia). The non-specifically bound protein was washed from the column under stringent conditions using a series of three wash buffers. The primary wash was performed using 100ml of Binding buffer. This was followed by a high stringency low pH wash (20mM NaPO<sub>4</sub>, 500mM NaCl, 0.1% Triton X-100, pH5.5) and an additional high stringency wash using 100ml of 20mM NaPO<sub>4</sub>, 500mM NaCl, 0.1% Triton X-100, 50mM Imidazole, pH7.4.

The histidine-tagged recombinant proteins were eluted from the column by stripping with 50mM EDTA. Eluted proteins were dialysed overnight against 1x PBS to remove EDTA and Ni contaminants. The purified protein was

concentrated and washed in sterile PBS using a 50000 Mw cutoff concentrator column (Millipore). The total amount of protein was determined by spectrophotometry using BSA as a standard with the bicinchoninic acid assay.

### Immunological studies in experimental arthritis

#### Antibody response to p78 in experimental arthritis

Collagen arthritis (CIA) and pristane arthritis (PIA) were induced in DBA/1 mice according to our previously described protocol. Mice were bled before induction of arthritis (15 animals), at the onset of CIA (16 animals) and the onset of PIA (14 animals). The antibody in mouse sera against p78 was determined using an enzyme-linked immunosorbent assay (ELISA) with recombinant p78. Nunc 96-well ELISA plates (Fisher Biotech, Orangeburg, NY) were coated overnight at 4°C with p78 at 500 ng (in 100 ml of 5% non-fat milk/PBS) per well. After washing 3 times with phosphate buffered saline (PBS) containing 0.05% Tween-20, the plate was blocked with 5% non-fat milk/PBS overnight at 4°C. The mouse sera were added into the wells at 1:200 dilution in milk/PBS and incubated overnight at 4°C. The plate was washed. 100 ml goat anti-mouse Ig conjugated with alkaline phosphatase (anti-Ig-AK: 1:500 dilution in milk/PBS/Tween-20, Fisher Biotec) was added for 60 mins at 37°C. After three washes with PBS/Tween-20, 100 ml paranitrophenyl phosphphate solution (PNPP tablets; Sigma Chemicals; St Louis, MO) in diathylanolamine buffer was added to each well. The reaction was allowed to proceed for 30 mins in the dark and the plate read at 405nm in aspectrophotometer (Molecular Devices, Menlo Park, CA). The data were analyzed using the SOFTmax analytical software package. The specific

binding were the OD readings from p78-coated wells subtracting the OD from non-coated as well as non-sera blanks. The antibody levels were expressed as OD<sub>405</sub> units.

## RESULTS

### Identification of autoantigen

When RA and control sera were blotted against chondrocyte extracts, 30% RA sera reacted with a 78 Kd protein compared to 10% of control sera (Figure 1). Sequencing of three tryptic peptides by low energy CAD identified one component of the 78 kD band as the 78 kD glucose-regulated protein, also known as immunoglobulin heavy chain binding protein (BiP). DNA sequence analysis of p78 from articular chondrocyte cDNA showed a number of deviations from the published sequence (accession number X87949). A total of six single nucleotide substitutions and a codon insertion result in three amino acid substitutions and an arginine insertion at position 834-836 of p78 (accession number AF188611).

### Immunological tests in rheumatoid arthritis

T cell proliferative responses were determined for mononuclear cell preparations from paired peripheral blood and synovial fluid samples obtained from 23 patients with rheumatoid arthritis and from 12 disease controls. Twelve of 23 (52 per cent) patients with RA and only 2 of 12 (17 per cent) of disease controls showed increased synovial proliferation (Figure 2). The proliferative response to p78 of RA synovial T cells was significantly higher than that of the paired peripheral blood (stimulation index, mean  $\pm$  SEM: SF  $3.5 \pm 0.7$ ; PB  $1.6 \pm 0.2$ ;  $p < 0.01$  Wilcoxon paired test). A significant difference was also seen between synovial fluid responses to p78 between RA

patients and disease controls (SI: RA  $3.5 \pm 0.7$ ; OIJD  $1.4 \pm 0.2$ ;  $p=0.03$  Mann Whitney U test). There was no association with HLA-DR as 50% of responders and non-responders were HLA-DR4 positive (data not shown).

Rheumatoid synovial fluid T cell proliferation to p78 was inhibited by 66-84% by anti-HLA-DR monoclonal antibody L243 (ATCC, Rockville, MD) (data not shown).

No IFN $\gamma$  could be measured in the supernatants from the paired synovial fluid and peripheral blood mononuclear cells (data not shown) despite using an ELISA sensitive to 0.01 ng/ml. No IFN $\gamma$  could be detected by intracellular fluorescence in the peripheral blood T cells of RA patients ( $n = 7$ ) or healthy controls ( $n = 2$ ) after stimulation by p78 (data not shown). These findings imply that the responding T cells were unlikely to belong to the classical IFN $\gamma$  producing TH1 subset{1461}.

#### Immunological studies in experimental arthritis

##### Induction of experimental arthritis with p78

Immunisation of DBA/1, C57BL mice and Lewis rats with p78 in Freund's complete adjuvant (CFA) did not lead to the development of arthritis (data not shown). There was a similar lack of arthritogenicity of p78 when injected with CFA into HLA-DR1<sup>+/+</sup> (0/10 mice) or into HLA-DR4<sup>+/+</sup> (0/5) mice.

##### Immune response to p78 in experimental arthritis

Despite the failure to induce arthritis by immunising animals with p78, we investigated whether DBA/1 mice during the course of collagen (CIA) or pristane (PIA) induced arthritis developed antibodies to p78 (Figure 4). Mice developed serum anti-p78 antibodies at the onset of collagen arthritis (O.D<sub>405</sub>.

$0.189 \pm 0.042$ ,  $m \pm \text{sem}$ ) and pristane induced arthritis ( $0.504 \pm 0.074$ ) when compared to pre-bleed sera ( $0.070 \pm 0.019$ ;  $p < \text{versus CIA}$  and  $p < \text{versus PIA}$ , respectively). Furthermore the concentration of these antibodies was significantly higher in the PIA mice as compared to CIA mice ( $p < \text{versus CIA}$ ). There were 14 mice in each group.

#### Prevention of collagen-induced arthritis by intravenous administration of p78

The presence of antibodies to p78 in the sera of mice with CIA or PIA suggested that manipulating the immune response to p78 might prevent the subsequent development of CIA by a bystander phenomenon. HLA-DR1<sup>+/+</sup> transgenic mice were injected intravenously with 1mg of p78 prior to immunisation with type II collagen in CFA one week later (Table 2). Whereas 83% of animals had 46% of their limbs involved with arthritis at 8 weeks when pretreated with saline, only 10% of animals had 3% of their limbs involved with arthritis in the group previously given intravenous p78. These differences are highly significant ( $p \leq 0.008$  and  $p \leq 0.0001$ ). Table 2 also shows that there was a significant reduction in anticollagen antibodies in the p78 pre-treated animals to one third the level in the controls. The reduction was equal in the the IgG1 and IgG2 isotypes (Table 3). The histology of the joints of these animals (Figure 6) confirmed the clinical findings in that there was no synovitis in the joints of p78 pre-treated mice.

We have shown in this study that 30% of patients with RA have antibodies, detected by Western blotting, directed against the human chaperonin BiP/GRP78, and named by us p78. Furthermore, T cells from the rheumatoid synovial fluid proliferated preferentially to p78. There was minimal response by the T cells from the peripheral blood of the same patients. The T cells from



patients with other inflammatory arthritides, whether from the synovial fluid or the peripheral blood, did not significantly proliferate to p78. Finally, the proliferative response was inhibited by anti-HLA-DR monoclonal antibody suggesting that CD4+ positive T cells are responding to antigenic peptides presented in the context of HLA-DR. This polyclonal T cell response was not HLA-DR4 restricted. Thus p78 stimulation of T cell proliferation possesses two characteristics to be expected of a rheumatoid autoantigen, namely, it is joint and disease specific.

On the basis of these observations, we then undertook intravenous immunisation of mice with p78 in order to test the hypothesis that deviating the immune response to p78 would prevent the development of CIA by a bystander mechanism. This indeed proved to be the case with almost total prophylaxis against the induction of CIA in HLA-DR1<sup>+/+</sup> transgenic mice. In the past, various types of experimental arthritis have been prevented or treated by administration of bacterial, and especially mycobacterial, heat shock proteins such as HSP60 or T cells responding to whole HSP60 or to specific peptides{2103, 2280,2282,2283,2284,2281}. However, it is of some importance to note that self-HSP60 peptides show no such protective effects{2281}. Thus the ability of p78 to prevent CIA is of fundamental importance. The observations described in this work are the first, to our knowledge, which implicate an endogenous chaperone in the pathogenesis of RA and the immunotherapy of experimental arthritis. The potential for the immunotherapy of RA is clearly apparent.

## 2. Use of tests for detection of antibodies to p78 in biological fluids or culture supernatants

Several techniques can be used, such as agglutination, Western blotting, and ELISA.

### ELISA protocol for the detection of antibodies to p78 in sera

ELISA plates are coated half with p78 in bicarbonate buffer and half with bicarbonate buffer alone for 4 hours at room temperature. After 2 washes in PBS the plate is blocked for 2 hours at room temperature with 10% goat serum in PBS with 0.05% Tween 20 to stop non-specific binding of protein. After 2 further washes diluted sera (in PBS/1% goat serum/0.05% Tween) is added in duplicate to both the p78 coated and non-coated sides of the plate. After 4 washes biotin conjugated anti human immunoglobulin (1/10000 diluted in PBS/1% goat serum/0.05% Tween)) is added to the plate. The plate is washed 6 times. Bound biotinylated antibody is detected with streptavidin conjugated horse-radish peroxidase (1/800 in PBS/1% goat serum/0.05% Tween) and suitable substrate. Sera containing antibodies to p78 are determined spectrophotometrically. This test forms the basis of a diagnostic and/or prognostic test for rheumatoid arthritis.

## 3. Therapeutic application

Many routes of administration of the recombinant protein or vector are possible, including intravenous, intramuscular, nasal, oral, cutaneous, and topical. There are several approaches to using p78 or derivatives for therapeutic purposes, including the following:

(a) Induction of mucosal tolerance.

Delivery of p78 autoantigen or peptides derived therefrom by mucosal routes, e.g. through the intestine or nasal mucosa, alters the immune response by downregulating disease activity leaving the patient's immune system otherwise intact. Alternatively p78 or p78 peptides can be delivered as DNA plasmids encoding them with an appropriate mammalian expression vector.

(b) Vaccination with TCR peptides

Peptides of the CDR3 region of the T cell receptor V $\alpha$  and V $\beta$  chains can be synthesised and used as vaccines for delivery by intradermal or intramuscular injection. Plasmids encoding these peptides can be used in the same way.

(c) MHC blockade with native or altered peptides

The p78 peptides may be given parenterally or orally in appropriate cases either unmodified or modified by amino acid substitution and/or attachment of chemical groupings so as to block MHC and especially HLA-DR4 thereby leading to suppression of T cell activation and disease. P78 peptides either native or altered may be combined with soluble HLA-DR4 molecules and applied parenterally or orally.

(d) Induction of tolerance by plasmid DNA immunisation

Plasmids consisting of DNA coding for whole p78 protein or its peptides linked to a mammalian expression vector may be given by injection. DNA coding for human IL-10, IL-4, IL-11, or TGF-beta, incorporated singly or in any combination, may be used to deviate the immune response to p78 towards a TH2 mode so as to suppress disease.

In the therapeutic regimes indicated above the protein or derived peptide may be administered in appropriate compositions delivering amounts ranging from about 0.1 micrograms to about 1 gram or the equivalent in the case of plasmid or vaccine preparations.

### Appendix 1

#### Methodology for gel electrophoresis

##### Acrylamide gel: 10%

6.075ml acrylamide (40%) (BDH, Poole, UK)

3.35ml methylenbisacrylamide (2%)(Pharmacia Biotech, Uppsala, Sweden)

6.25ml acrylamide gel buffer (see below)

9ml distilled water (produced within the laboratory)

250µl Ammonium persulphate (AMPERS)(0.025mg in 250ul of distilled water)(Sigma-Aldrich, Poole, UK)

25µl NNNN'-Tetramethylethylenediamine (TEMED)(Sigma-Aldrich, Poole, UK)

##### Acrylamide gel buffer: pH 8.8

1.5M Tris (tris(hydroxymethyl)aminomethane)(Sigma-Aldrich, Poole, UK)

pH titration with concentrated hydrochloric acid

0.4% Sodium dodecyl sulphate (SDS)(BDH-Merck, Poole, UK)

##### Stacking gel:

1.2ml acrylamide (40%)(BDH-Merck, Poole, UK)

0.65ml bisacrylamide (2%)(Pharmacia Biotech, Uppsala, Sweden)

3.15ml stacking gel buffer (see below)

7.5ml distilled water (produced within the laboratory)

125µl ammonium persulphate (AMPERS) (0.025mg/250µl)(Sigma-Aldrich, Poole, UK)

12.5µl NNN'N'-Tetramethylethylenediamine (TEMED)(Sigma-Aldrich, Poole, UK)

Stacking gel buffer: pH 6.8:

0.5M Tris (tris(hydroxymethyl)aminomethane)(Sigma-Aldrich, Poole, UK)

pH titration with concentrated hydrochloric acid

0.4% Sodium dodecyl sulphate (SDS)(BDH-Merck, Poole, UK)

Loading buffer:

2ml glycerol

2ml 10% Sodium dodecyl sulphate (SDS)(BDH-Merck, Poole, UK)

0.25mg bromophenol blue

2.5ml stacking gel buffer 4-times concentrated (0.5M Tris; 0.4% SDS; pH 6.8)

0.5ml 2-mercaptoethanol (Sigma-Aldrich, Poole, UK)

Electrophoresis/Running buffer:

3g/l Tris (tris(hydroxymethyl)aminomethane)(Sigma-Aldrich, Poole, UK)

14.4g/l glycine (BDH-Merck, Poole, UK)

1g/l Sodium dodecyl sulphate (SDS)(BDH-Merck, Poole, UK)

Transfer buffer:

3g/l Tris (tris(hydroxymethyl)aminomethane)(Sigma-Aldrich, Poole, UK)

14.4g/l glycine (BDH-Merck, Poole, UK)

1g/l Sodium dodecyl sulphate (SDS)(BDH-Merck, Poole, UK)

14.4g/l glycine (BDH-Merck, Poole, UK)

10% methanol (BDH-Merck, Poole, UK)

Tris Tween buffered saline (TTBS):

2.4g/l Tris (tris(hydroxymethyl)aminomethane)(Sigma-Aldrich, Poole, UK)

29g/l sodium chloride (BDH-Merck, Poole, UK)

500µl tween 20 (polyoxyethylene-sorbitan mono-laurate)(Sigma-Aldrich, Poole, UK)

3% Bovine serum albumin solution (BSA):

3g Albumin bovine fraction 5 (BDH-Merck, Poole, UK)

100ml TTBS (see above)

## Appendix 2

Amino acid sequence of the expressed BiP recombinant human protein. Total 1917 nucleotides. Starting at Methionine (start codon) ending in 6X His tag.

Molecular Weight 70937.50 Daltons

639 Amino Acids

86 Strongly Basic(+) Amino Acids (K,R)

108 Strongly Acidic(-) Amino Acids (D,E)

204 Hydrophobic Amino Acids (A,I,L,F,W,V)

142 Polar Amino Acids (N,C,Q,S,T,Y)

5.173 Isoelectric Point

-20.041 Charge at pH 7.0

MEEDKKEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVFTPEGERLIGDAAKNQLTSNPENTVFDKRL  
IGRTWNPDPSVQQDIKFLPFKVVVEKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAAYLGKKVTHAVVTVPAYFND  
AQRQATKDAGTIAGLNMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDF  
DQRVMEHFILKYKKTGKDVKDNRAVQKLRRVEKAKRALSSQHQAIEIESFYEGEDFSETLRAKFEELNMDLFRST  
MKPVQKVLESDLKKSDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLD  
VCPLTLGIETVGGVMTKLIPRNTVVPVKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTDLTGIPAPRGVPQIE  
VTFEIDVNGILRVTAEDKGTGNKNKIIITNDQNRLTPEELERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGD  
KEKLGKGLSSEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSAGPPPTGEEDTAELEHHHHH



## Appendix 3

RT-PCR Cloned and Sequenced *grp78* (BiP) fragment used for expression of recombinant human protein. Total 1917 nucleotides. Starting at ATG start codon ending in 6X His tag.

```
ATGGAGGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACCTGGGGACCACTACTCCTGCGTCGGCGTGTT
CAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGCATCACGCCGCTCCTATGTCGCCTTCACTCCTGAAG
GGGAACGCTGATTGGCGATGCCGCCAAGAACCAGCTCACCTCCAACCCCGAGAACACGGGCTTTGACGCCAAGCGGCTC
ATCGGCCGCACGTGGAATGACCCGCTCTGTGCAGCAGGACATCAAGTTCTTGCCGTTCAAGGTGGTTGAAAAGAAAACTAA
ACCATACATTCAAGTTGATATTGGAGGTGGGCAACAAAGACATTGCTCCTGAAGAAATTTCTGCCATGGTTCTCACTA
AAATGAAAGAAACCGCTGAGGCTTATTTGGGAAAGAAGTTACCCATGCAGTTGTTACTGTACCAGCCTATTTTAAATGAT
GCCCCAACGCCAAGCAACCAAGACGCTGGAATATTGCTGGCCTAAATGTTATGAGGATCATCAACGAGCCTACGGCAGC
TGCTATTGCTTATGGCCTGGATAAGAGGGAGGGGAGAAGAACATCCTGGTGTGTTGACCTGGGTGGCGGAACCTTCGATG
TGCTCTTCTCACCATTTGACAATGGTGTCTTCGAAGTTGTGGCCACTAATGGAGATACTCATCTGGGTGGAGAAGACTTT
GACCAGCGTGTCTATGGAACACTTCATCAAATGTACAAAAAGAAGACGGGCAAGATGTCAGGAAGACAATAGAGCTGT
GCAGAACTCCGGCGCGAGGTAGAAAAGGCCAAACGGGCCCTGTCTTCTCAGCATCAAGCAAGAATTGAAATTTGAGTCTCT
TCTATGAAGGAGAAGACTTTTCTGAGACCTTGACTCGGGCCAAATTTGAAGAGCTCAACATGGATCTGTTCCGGTCTACT
ATGAAGCCCGTCCAGAAAGTGTGGAAAGATTCTGATTGAAGAAGTCTGATATTGATGAAATTTGTTCTGTTGGTGGCTC
GACTCGAATTCCAAAGATTGAGCAACTGGTTAAAGAGTTCTTCAATGGCAAGGAACCATCCCGTGGCATAAACCCAGATG
AAGCTGTAGCGTATGGTGTCTGTCTCCAGGCTGGTGTCTCTCTGGTGATCAAGATACAGGTGACCTGGTACTGCTTGTAT
GTATGTCCCTTACACTTGGTATTGAAACTGTGGGAGGTGTCATGACCAAACCTGATTCCAAGGAACACAGTGGTGCCTAC
CAAGAAGTCTCAGATCTTTTCTACAGCTTCTGATAATCAACCAACTGTTACAATCAAGGTCTATGAAGGTGAAAGACCCC
TGACAAAAGACAATCATCTTCTGGGTACATTGTATCTGACTGGAATTCCTCTGCTCCTCGTGGGGTCCCACAGATTGAA
GTCACCTTTGAGATAGATGTGAATGGTATTCTCGAGTGACAGCTGAAGACAAGGTCACGGGAACAAAAATAAGATCAC
AATCACCAATGACCAGAATCGCCTGACACCTGAAGAAATCGAAAGGATGGTTAATGATGCTGAGAAGTTTGTCTGAGGAAG
ACAAAAAGCTCAAGGAGCGCATTGATACTAGAAATGAGTTGGAAGCTATGCCTATTCTCTAAAGAATCAGATTGGAGAT
AAAGAAAAGCTGGGAGGTAAACTTTCCTCTGAAGATAAGGAGACCATGGAAAAAGCTGTAGAAGAAAAGATTGAATGGCT
GGAAGCCACCAAGATGCTGACATTGAAGACTTCAAAGCTAAGAAGAAGGAAGTGAAGAAATTTGTTCAACCAATTATCA
GCAAACTCTATGGAAGTGCAGGCCCTCCCCAACTGGTGAAGAGGATACAGCAGAACTCCACCACCACCACCACCAC
```

[illegible][illegible]

tgcgtat tgc tttat ggctgtat taagaggaggaggggagaagaacat cctgggtgttt gacctgggtggcggaaccttc  
 gtgtgtctcttc cccat tgcacat tgggtgtt cttcgaaagt tctggccacta atggagata tcatctctgggtggaga  
 agactt tgcacagcgtgt tca tggacact tcatcaactgt caaaaaagaacgcgggcaagaatgtcagggaagga  
 atagagctgt tgcagaataactccggcgaggatagaagaagccgaagccctgt cttctcagcat caagcaagaat tga  
 attgagtctctt at taagggaagaactt tctgcagacctgactccggccaactt tgaagact caacatggatct  
 gttccctctct act atgaagccctgcagaagaatgt tggagaagtctgtatt tgaagaagtctgtat tga tgaattgt  
 tctctgttgggtgctgactcgaattccaagaatctcagcaactggt taaagaattt cttcaatggcaaggaaccttc  
 cgtggcataaa cccagat gaagctgtagctgtatgtgtctgtcgtccagcctggtgtgagctctctgtgtatcaagaatc  
 aggtgacctggtctctctctgtatgtcccttccacttgggtat tgaacctgtaggaggtgtctatgaccaactga  
 ttccaagtaatacagttggtgcttaccagaactctcagatctt tttctacagcttctgtataatcaacaaactgttaca  
 atcaaggtcttataagaggttaagagccctgcagcaaaagacatcatctctgggtacattt tgaatctgactggaattcc  
 tctgtctctctgtgggtgccacagat tgaagtcactt tgaagatagatgtaattggatattcttcagatgcagctgt  
 aaagcaagggtacagggaacaaaaataagatcacaatcaccaatgaccagaatcgcctgacacctgaaggaatcgaa  
 aggatggttaatagtgctcgaaa  
 gtttctgtagggaacaaaaagctcaaggagcgcat tgtatactagaataatgttggaaagctatgcttaactctaa  
 aagatcagat tggagataaaaaagagctgggaagttaaacttctctgaagtaaaagagacatgacaaatgctgtta  
 gaagaagaagattgaatggcttggaaagccaaagatgctgacattgaagacttcaaagctaaagaaggaaactgga  
 agaaaattgt tcaaccaaattcagcaaaactctatggaagctcgaggccctcccccaactggttgaagaggaacacagga  
 aaaaaagtagtttgcagacatgtctctagtcgtgtaattt tgaataactggactcaggaacttt tgt taggaa  
 aaaaattgaaagaaccttaagctctgaattgaatttggaaattccacctcagaggtggagttgaaactgctatagctcaagc  
 ggctgtt tctactgcttttctatagcagatgtctcacatgtct tgggtgggggggagaagaagaatttggccctttaa

## Appendix 4 (contd)

aaagcgggtataaaacctgggttaggggtgtgttcacottcaaaatgttctattttaacaactgggtcatgtgcac  
 tgggtgtaggaagtttttctaccataaagtgcaccaataaatgttgttatttacctgggtcaaaaaaaaaaaaaa  
 aa□

**Table 1.** Prevention of CIA by intravenous injection of recombinant p78

Tolerogen <sup>a</sup>	% Arthritic Mice at 8 weeks <sup>b</sup>	% Arthritic Limbs at 8 weeks <sup>b</sup>	Antibodies (IgG) to CII <sup>c</sup>
p78 (1mg)	1/10 (10%)*	1/40 (3%)**	22 ± 9***
PBS	5/6 (83%)	11/24 (46%)	68 ± 10

<sup>a</sup> HLA-DR1<sup>+/+</sup> transgenic mice were injected intravenously with either PBS (negative control) or recombinant p78. Either 1mg of protein dissolved in 0.1ml of PBS or 0.1ml of PBS was administered intravenously and mice were immunised with type II collagen in CFA seven days after the intravenous dose.

<sup>b</sup> The incidence of arthritis is reported at 8 weeks after immunisation.

<sup>c</sup> Antibodies represent mean units per group using sera collected 8 weeks after immunisation. ELISAs were performed and results are reported as units of activity derived by comparison of test sera with the standard serum which was arbitrarily defined as having 50 units of activity. Sera were analysed individually and results shown as the mean ± SD for each group of animals.

\*  $p \leq 0.008$  (Fischer's Exact test) \*\*  $\leq 0.0001$  (Fischer's Exact test) \*\*\*  $< 0.05$  (Students t test)

**Table 2.** IgG1 and IgG2 antibody isotypes to type II collagen in mice treated intravenously with either recombinant p78 or PBS.

Tolerogen <sup>a</sup>	IgG1 antibodies to type II collagen <sup>b</sup>	IgG2 antibodies to type II collagen <sup>b</sup>
p78 (1000 µg)	0.71 ± 0.019 *	0.110 ± 0.022 *
PBS	0.135 ± 0.066	0.250 ± 0.044

a HLA-DR1 transgenic mice were injected intravenously with either PBS (negative control) or recombinant p78 followed by immunisation with collagen type II in CFA one week later.

b ELISAs were performed as described in caption to Table 2.

\*p<0.05 (Students t test)

Table 3: Anti-p78 antibody in CIA or PIA mouse sera (1:200 dil)

Subtract blanks and non-coated values			
Mouse ID	Prebleed	CIA onset	PIA(mouse ID#1-14)
961	0.000	0.243	0.263
982	0.181	0.328	0.981
963	0.155	0.567	0.780
965	0.076	0.198	0.934
966.	0.162	0.257	0.388
967	0.068	0.000	0.291
968	0.039	0.189	0.469
970	0.000	0.000	0.551
197	0.173	0.000	0.537
198	0.023	0.000	0.711
200	0.000	0.099	0.430
248	0.000	0.183	0.535
702	0.090	0.011	0.038
703	0.012	0.206	0.147
705		0.341	
706		0.407	
Mean	0.070	0.189	0.504
Count	14	16	14
SEM	0.019	0.042	0.074

**Legends to figures****Figure 1**

Western blotting showing 6 rheumatoid sera (lanes 1-6), 5 normal sera (lanes 7-11) and 4 disease controls (lanes 12-15) reacting with chondrosarcoma lysate. Molecular weight markers are shown.

**Figure 2**

Lymphocyte proliferation in mononuclear cells cultured for 6 days expressed as a stimulation index: proliferation in the presence of p78/proliferation in the presence of culture medium alone. A stimulation of  $\geq 2.5$  was considered significant. RAPB, rheumatoid arthritis peripheral blood; RASF, rheumatoid arthritis synovial fluid; OIJD PB, other inflammatory joint diseases peripheral blood; OIJD SF, other inflammatory joint diseases synovial fluid.

**Figure 3**

Antibodies to recombinant human p78 in the sera of mice measured by ELISA and expressed as OD<sub>405</sub>. Shown are the values for the animals bled before the induction of experimental arthritis (pre-bleed), and at the onset of collagen-induced arthritis (CIA) and of pristane-induced arthritis (PIA).

## References

## Bibliography

1. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. **Arthritis Rheum.** 1987; **30**: 1205-1213.
2. Panayi GS. T cell dependent pathways in rheumatoid arthritis. **Current Opinion in Rheumatology** 1997; **9**: 236-240.
3. Sakata A, Sakata K, Ping H, Ohmura T, Tsukano M, Kakimoto K. Successful induction of severe destructive arthritis by the transfer of in vitro activated synovial fluid T cells from patients with rheumatoid arthritis (RA) in severe combined immunodeficient (SCID) mice. **Clin Exp Immunol** 1996; **104**: 247-254.
4. Ikeda Y, Masuko K, Nakai Y, et al. High frequencies of identical T cell clonotypes in synovial tissues of rheumatoid arthritis patients suggest the occurrence of common antigen-driven immune responses. **Arthritis & Rheumatism** 1996; **39**: 446-453.
5. Uematsu Y, Wege H, Strauss A, et al. The T cell receptor repertoire in the synovial fluid of a patient with rheumatoid arthritis is polyclonal. **Proc Natl Acad Sci** 1991; **88**: 8534-8538.
6. Cope AP, Sonderstrup G. Evaluating candidate autoantigens in rheumatoid arthritis. **Springer Seminars in Immunology** 1998; **20**: 23-39.
7. Laine VA. Early synovectomy in rheumatoid arthritis. [Review] [87 refs]. **Annual Review of Medicine** 1967; **18**: 173-184.
8. Laskin RS. Total condylar knee replacement in patients who have rheumatoid arthritis. A ten year follow-up study. **J Bone Jt Surg (Am)** 1991; **72**: 529-535.
9. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. **Nature** 1970; **227**: 680-685.
10. Towbin H, Staehelin T, Gordon T. Electrophoretic transfer of proteins from SDS and acid/urea gels to nitrocellulose. **Proc Nat Acad Sci** 1979; **76**: 4350
11. Jobanputra P, Corrigan V, Panayi GS. Expression of the 65 kD heat shock protein in human chondrocytes. **Brit J Rheumatol** 1993; **32**: 259-230.
12. Bunce M, O'Neill CM, Barnado MCNM, et al. Phototyping comprehensive DNA typing for HLA-A, B, C, DRB3, DRB5 and DQB1 by PCR with 144 primer mixes utilising sequence-specific primers (PCR-SSP). **Tissue Antigens** 1995; **46**: 355-367.

REF

\*\*\*\*\* Not found in the database "SAMPLE"



14. Mossman TR, Cherwinski H, Bond MW, Giedlin MA, Coffman KL. Two types of murine T helper T cell clones: 1 definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 1986; **136**: 2348-2356.

15. Auger I, Roudier J. A function for the QKRAA amina acid motif: mediating binding of DnaJ to DnaK. Implications for the Association of Rheumatoid Arthritis with HLA-DR4. *J Clin Invest* 1997; **99**: 1818-1822.

16. van Shooten WCA, Devereux D, Ho CH, Aguilar BA, Rust CJJ. Joint derived T cells in rheumatoid arthritis react with self-immunoglobulin heavy chains or immunoglobulin binding proteins that copurify with immunoglobulin. *Eur J Immunol* 1945; **23**: 93-98.

17. Knarr G, Gething M, Modrow S, Buchner J. BiP binding sequences in antibodies. *J Bio Chem* 1995; **46**: 27589-27594.

18. Winfield JB. Stress proteins, arthritis and autoimmunity. *Arthritis & Rheum* 1989; **32**: 1497-1504.

19. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. *Immunity* 1998; **8**: 657-665.

20. Arnold-Schild D, Hanau D, Spohner D, et al. Cutting Edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. *J Immunol* 1999; **162**: 3757-3760.

0000000000000002603 \*\*\*\*\* Not found in the database "SAMPLE"

22. Blass S, Burmester G. Anti-BiP antibodies in rheumatoid arthritis: method and test kits for detecting them. 1999; **WO 99/18131**: (Abstract)

23. Rosloniec EF, Brand DD, Myers LK, et al. Induction of autoimmune arthritis in HLA-DR4 (DRB1\*0401) transgenic mice by immunization with human and bovine type II collagen. *J Immunol* 1998; **160**: 2573-2578.

24. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. [Review] [144 refs]. *Life Sciences* 1997; **61**: 1861-1878.

25. Wooley PH, Sud S, Whalen JD, Nasser S. Pristane-induced arthritis in mice. V. Susceptibility to pristane-induced arthritis is determined by the genetic regulation of the T cell repertoire. *Arthritis & Rheumatism* 1998; **41**: 2022-2031.

26. Kouskoff V, Korganow A, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. *Cell* 1996; **67**: 811-822.

27. Verheijden GF, Rijnders AW, Bos E, et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. *Arthritis & Rheumatism* 1997; **40**: 1115-

28. Low-Friedrich I, Weisensee D, Mitrou P, Schoeppe W. Cytokines induce stress protein formation in cultured cardiac myocytes. **Basic Research in Cardiology** 1992; **87**: 12-18.
29. Haskins K, Wegmann D. Diabetogenic T-cell clones. [Review] [49 refs]. **Diabetes** 1996; **45**: 1299-1305.
30. Hirvonen MR, Brune B, Lapetina EG. Heat shock proteins and macrophage resistance to the toxic effects of nitric oxide. **Biochemical Journal** 1996; **315**: 845-849.
31. Beech JT, Siew LK, Ghoraishian M, Stasiuk LM, Elson CJ, Thompson SJ. CD4+ Th2 cells specific for mycobacterial 65-kilodalton heat shock protein protect against pristane-induced arthritis. **J Immunol** 1997; **159**: 3692-3697.
32. van Eden W, Thole JE, van der Zee R, et al. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. **Nature** 1988; **331**: 171-173.
33. van den Broek MF, Hogervorst EJ, van, et al. Protection against streptococcal cell wall-induced arthritis by pretreatment with the 65-kD mycobacterial heat shock protein. **J Exp Med** 1989; **170**: 449-466.
34. Thompson SJ, Rook GA, Brealey RJ, van, der Zee R, Elson CJ. Autoimmune reactions to heat-shock proteins in pristane-induced arthritis. **Eur J Immunol** 1990; **20**: 2479-2484.
35. Billingham ME, Carney S, Butler R, Colston MJ. A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic. **J Exp Med** 1990; **171**: 339-344.
36. Anderton SM, van der, Zee R, et al. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. **J Exp Med** 1995; **181**: 943-952.

## CLAIMS

1. The use of immunoglobulin heavy chain binding protein BiP (GRP78), or a peptide derived therefrom, as a reagent for indicating the presence of rheumatoid arthritis.
2. The use of protein BiP(GRP78) according to claim 1, in which the protein has the amino-acid sequence of Sequence Listing SEQ.ID.No.1 or SEQ.ID.No.2.
3. The protein BiP(GRP78) having the amino-acid sequence of Sequence Listing SEQ.ID.No.1 or SEQ.ID.No.2.
4. Recombinant BiP(GRP78).
5. A prognostic or diagnostic test for RA in which the test reagent for testing body fluid is immunoglobulin heavy chain binding protein BiP (GRP78), or a peptide derived therefrom.
6. A test according to claim 5, being an ELISA assay.
7. A test according to claim 5, being a Western Blot.
8. Immunoglobulin heavy chain binding protein BiP (GRP78), or a peptide derived therefrom, for use in therapy.

9. Immunoglobulin heavy chain binding protein BiP (GRP78), or a peptide derived therefrom, for use in rheumatoid arthritis therapy.
10. A cDNA sequence coding for Immunoglobulin heavy chain binding protein BiP (GRP78), or for a peptide derived therefrom, for use in therapy.
11. A cDNA sequence coding for Immunoglobulin heavy chain binding protein BiP (GRP78), or for a peptide derived therefrom, for use in rheumatoid arthritis therapy.
12. A cDNA sequence having or containing the nucleotide sequence of Sequence Listing SEQ.ID.No.3.
13. A recombinant vector containing a DNA sequence according to claim 12.
14. A method of testing for RA, using a protein BiP(GRP78) or a cDNA sequence coding therefor to determine the presence of antibodies to said protein.
15. A method of therapeutic treatment of RA comprising administering the protein BiP(GRP78) or a DNA coding therefor.
16. Method according to claim 15, in which administration is by the intravenous, nasal, oral, or cutaneous route.
17. A recombinant organism capable of expressing protein BiP(GRP78).

1 / 3





FIG. 1

2 / 3


FIG. 2

PROLIFERATIVE RESPONSES TO P78



3 / 3

FIG. 3

ANTI-P78 ANTIBODY IN CIA AND PIA  
MOUSE SERA (1/200 DILUTION)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): PANAYI, Gabriel S., et al. Atty. Docket: 78104.023  
 Title: TREATMENT OF INFLAMMATORY DISEASE

### DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Each undersigned inventor hereby declare(s) that:

- My residence, post office address and citizenship are as stated below next to my name.
- I believe that I am, in conjunction with any joint inventor(s) named herein, the original and first inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **TREATMENT OF INFLAMMATORY DISEASE**, the patent application for which was filed as PCT international application number PCT/GB99/03316 on 08 October 1999, was amended on 05 October 2000, and which is amended by a preliminary amendment filed with this document.
- I reviewed and understand the contents of the above-identified patent application, including the specification and claims, as amended by any amendments referred to above.
- I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability, as defined in Section 1.56 of Title 37, U.S. Code of Federal Regulations.
- Foreign priority benefits are claimed under Title 35, U.S. Code §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below. Also identified below are any foreign applications for patent or inventor's certificate, or any PCT international application having a filing date before that of the application for which priority is claimed.

<i>Application No.</i>	<i>Country</i>	<i>Day/Month/Year</i>	<i>Priority Claimed</i>
PCT/GB99/03316	PCT	08 October 1999	YES
GB 9822115.3	Great Britain	09 October 1998	YES

*I APPOINT* the following registered practitioner(s) to prosecute this application and to transact all related business in the U.S. Patent and Trademark Office: Craig A. Fieschko (39,668), Joseph T. Leone (37,170), Charles S. Sara (30,492).

Address all telephone calls to:

Joseph T. Leone  
 Telephone: (608) 828-0743  
 Facsimile: (608) 831-2106



Address all correspondence to:

Intellectual Property Department  
DEWITT ROSS & STEVENS S.C.  
Firstar Financial Centre  
8000 Excelsior Drive Suite 401  
Madison, WI 53717-1914

**I DECLARE THAT** all statements made herein of my own knowledge are true; all statements made on information and belief are believed to be true; that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001; and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Gyng Panayi  
Signature  
April 30 2001  
Month Day Year

First or Sole Inventor: Gabriel Stavros PANAYI  
Post Office Address: 14 Westlinton Close  
London NW7 1PY  
England  
Citizenship: British

ENE 100

Valerie M Corrigan  
Signature  
April 30 2001  
Month Day Year

Second or Joint Inventor: Valerie Mary CORRIGALL  
Post Office Address: 25 Copley Way  
Tadworth, Surrey KT20 5QS  
England  
Citizenship: British

ENG 200

Mark Duncan  
Signature  
April 30 2001  
Month Day Year

Third or Joint Inventor: Mark Duncan BODMAN-SMITH  
Post Office Address: 285a Long Lane  
East Finchley, London N2 8JW  
England  
Citizenship: British

ENG 300

Mark Stewart Fife  
Signature  
April 30 2001  
Month Day Year

Fourth or Joint Inventor: Mark Stewart FIFE  
Post Office Address: 28 Archbishops Place  
Brixton, London SW2 2AJ  
England  
Citizenship: British

ENG 400

SSL  
Signature  
May 10<sup>m</sup> 2001  
Month Day Year

Fifth or Joint Inventor: Jeremy Shaun LANCHBURY  
Post Office Address: 10 Claremont Road  
Tunbridge Wells, Kent TN1 1SZ  
England  
Citizenship: British

5<sup>00</sup>  
ENG

09/806955

PCT/GB99/03316

WO 00/21995

## SEQUENCE LISTING

<110> KING'S COLLEGE LONDON  
 PANAYI, GABRIEL S  
 CORRIGALL, VALERIE M  
 BODMAN-SMITH, MARK D  
 FIFE, MARK S  
 LANCHBURY, JEREMY S

<120> TREATMENT OF INFLAMMATORY DISEASE

<130> N8862

<140>

<141>

<150> GB9822115.3

<151> 1998-10-09

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 639

<212> PRT

<213> Homo sapiens

<400> 1

Met Glu Asp Lys Lys Glu Asp Val Gly Thr Val Val Gly Ile Asp  
 1 5 10 15

Leu Gly Thr Thr Tyr Ser Cys Val Gly Val Phe Lys Asn Gly Arg Val  
 20 25 30

Glu Ile Ile Ala Asn Asp Gln Gly Asn Arg Ile Thr Pro Ser Tyr Val  
 35 40 45

Ala Phe Thr Pro Glu Gly Glu Arg Leu Ile Gly Asp Ala Ala Lys Asn  
 50 55 60

Gln Leu Thr Ser Asn Pro Glu Asn Thr Val Phe Asp Ala Lys Arg Leu  
 65 70 75 80

Ile Gly Arg Thr Trp Asn Asp Pro Ser Val Gln Gln Asp Ile Lys Phe  
 85 90 95

Leu Pro Phe Lys Val Val Glu Lys Lys Thr Lys Pro Tyr Ile Gln Val

100	105	110
Asp Ile Gly Gly Gly Gln Thr Lys Thr Phe Ala Pro Glu Glu Ile Ser 115	120	125
Ala Met Val Leu Thr Lys Met Lys Glu Thr Ala Glu Ala Tyr Leu Gly 130	135	140
Lys Lys Val Thr His Ala Val Val Thr Val Pro Ala Tyr Phe Asn Asp 145	150	155 160
Ala Gln Arg Gln Ala Thr Lys Asp Ala Gly Thr Ile Ala Gly Leu Asn 165	170	175
Val Met Arg Ile Ile Asn Glu Pro Thr Ala Ala Ala Ile Ala Tyr Gly 180	185	190
Leu Asp Lys Arg Glu Gly Glu Lys Asn Ile Leu Val Phe Asp Leu Gly 195	200	205
Gly Gly Thr Phe Asp Val Ser Leu Leu Thr Ile Asp Asn Gly Val Phe 210	215	220
Glu Val Val Ala Thr Asn Gly Asp Thr His Leu Gly Gly Glu Asp Phe 225	230	235 240
Asp Gln Arg Val Met Glu His Phe Ile Lys Leu Tyr Lys Lys Lys Thr 245	250	255
Gly Lys Asp Val Arg Lys Asp Asn Arg Ala Val Gln Lys Leu Arg Arg 260	265	270
Glu Val Glu Lys Ala Lys Arg Ala Leu Ser Ser Gln His Gln Ala Arg 275	280	285
Ile Glu Ile Glu Ser Phe Tyr Glu Gly Glu Asp Phe Ser Glu Thr Leu 290	295	300
Thr Arg Ala Lys Phe Glu Glu Leu Asn Met Asp Leu Phe Arg Ser Thr 305	310	315 320
Met Lys Pro Val Gln Lys Val Leu Glu Asp Ser Asp Leu Lys Lys Ser 325	330	335
Asp Ile Asp Glu Ile Val Leu Val Gly Gly Ser Thr Arg Ile Pro Lys 340	345	350
Ile Gln Gln Leu Val Lys Glu Phe Phe Asn Gly Lys Glu Pro Ser Arg		

355	360	365
Gly Ile Asn Pro Asp Glu Ala Val Ala Tyr Gly Ala Ala Val Gln Ala		
370	375	380
Gly Val Leu Ser Gly Asp Gln Asp Thr Gly Asp Leu Val Leu Leu Asp		
385	390	395
Val Cys Pro Leu Thr Leu Gly Ile Glu Thr Val Gly Gly Val Met Thr		
405	410	415
Lys Leu Ile Pro Arg Asn Thr Val Val Pro Thr Lys Lys Ser Gln Ile		
420	425	430
Phe Ser Thr Ala Ser Asp Asn Gln Pro Thr Val Thr Ile Lys Val Tyr		
435	440	445
Glu Gly Glu Arg Pro Leu Thr Lys Asp Asn His Leu Leu Gly Thr Phe		
450	455	460
Asp Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Val Pro Gln Ile Glu		
465	470	475
Val Thr Phe Glu Ile Asp Val Asn Gly Ile Leu Arg Val Thr Ala Glu		
485	490	495
Asp Lys Gly Thr Gly Asn Lys Asn Lys Ile Thr Ile Thr Asn Asp Gln		
500	505	510
Asn Arg Leu Thr Pro Glu Glu Ile Glu Arg Met Val Asn Asp Ala Glu		
515	520	525
Lys Phe Ala Glu Glu Asp Lys Lys Leu Lys Glu Arg Ile Asp Thr Arg		
530	535	540
Asn Glu Leu Glu Ser Tyr Ala Tyr Ser Leu Lys Asn Gln Ile Gly Asp		
545	550	555
Lys Glu Lys Leu Gly Gly Lys Leu Ser Ser Glu Asp Lys Glu Thr Met		
565	570	575
Glu Lys Ala Val Glu Glu Lys Ile Glu Trp Leu Glu Ser His Gln Asp		
580	585	590
Ala Asp Ile Glu Asp Phe Lys Ala Lys Lys Lys Glu Leu Glu Glu Ile		
595	600	605
Val Gln Pro Ile Ile Ser Lys Leu Tyr Gly Ser Ala Gly Pro Pro Pro		

610

615

620

Thr Gly Glu Glu Asp Thr Ala Glu Leu His His His His His His  
 625 630 635

&lt;210&gt; 2

&lt;211&gt; 633

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 2

Met Glu Glu Asp Lys Lys Glu Asp Val Gly Thr Val Val Gly Ile Asp  
 1 5 10 15

Leu Gly Thr Thr Tyr Ser Cys Val Gly Val Phe Lys Asn Gly Arg Val  
 20 25 30

Glu Ile Ile Ala Asn Asp Gln Gly Asn Arg Ile Thr Pro Ser Tyr Val  
 35 40 45

Ala Phe Thr Pro Glu Gly Glu Arg Leu Ile Gly Asp Ala Ala Lys Asn  
 50 55 60

Gln Leu Thr Ser Asn Pro Glu Asn Thr Val Phe Asp Ala Lys Arg Leu  
 65 70 75 80

Ile Gly Arg Thr Trp Asn Asp Pro Ser Val Gln Gln Asp Ile Lys Phe  
 85 90 95

Leu Pro Phe Lys Val Val Glu Lys Lys Thr Lys Pro Tyr Ile Gln Val  
 100 105 110

Asp Ile Gly Gly Gly Gln Thr Lys Thr Phe Ala Pro Glu Glu Ile Ser  
 115 120 125

Ala Met Val Leu Thr Lys Met Lys Glu Thr Ala Glu Ala Tyr Leu Gly  
 130 135 140

Lys Lys Val Thr His Ala Val Val Thr Val Pro Ala Tyr Phe Asn Asp  
 145 150 155 160

Ala Gln Arg Gln Ala Thr Lys Asp Ala Gly Thr Ile Ala Gly Leu Asn  
 165 170 175

Val Met Arg Ile Ile Asn Glu Pro Thr Ala Ala Ala Ile Ala Tyr Gly  
 180 185 190

Leu Asp Lys Arg Glu Gly Glu Lys Asn Ile Leu Val Phe Asp Leu Gly  
 195 200 205

Gly Gly Thr Phe Asp Val Ser Leu Leu Thr Ile Asp Asn Gly Val Phe  
 210 215 220

Glu Val Val Ala Thr Asn Gly Asp Thr His Leu Gly Gly Glu Asp Phe  
 225 230 235 240

Asp Gln Arg Val Met Glu His Phe Ile Lys Leu Tyr Lys Lys Lys Thr  
 245 250 255

Gly Lys Asp Val Arg Lys Asp Asn Arg Ala Val Gln Lys Leu Arg Arg  
 260 265 270

Glu Val Glu Lys Ala Lys Arg Ala Leu Ser Ser Gln His Gln Ala Arg  
 275 280 285

Ile Glu Ile Glu Ser Phe Tyr Glu Gly Glu Asp Phe Ser Glu Thr Leu  
 290 295 300

Thr Arg Ala Lys Phe Glu Glu Leu Asn Met Asp Leu Phe Arg Ser Thr  
 305 310 315 320

Met Lys Pro Val Gln Lys Val Leu Glu Asp Ser Asp Leu Lys Lys Ser  
 325 330 335

Asp Ile Asp Glu Ile Val Leu Val Gly Gly Ser Thr Arg Ile Pro Lys  
 340 345 350

Ile Gln Gln Leu Val Lys Glu Phe Phe Asn Gly Lys Glu Pro Ser Arg  
 355 360 365

Gly Ile Asn Pro Asp Glu Ala Val Ala Tyr Gly Ala Ala Val Gln Ala  
 370 375 380

Gly Val Leu Ser Gly Asp Gln Asp Thr Gly Asp Leu Val Leu Leu Asp  
 385 390 395 400

Val Cys Pro Leu Thr Leu Gly Ile Glu Thr Val Gly Gly Val Met Thr  
 405 410 415

Lys Leu Ile Pro Arg Asn Thr Val Val Pro Thr Lys Lys Ser Gln Ile  
 420 425 430

Phe Ser Thr Ala Ser Asp Asn Gln Pro Thr Val Thr Ile Lys Val Tyr  
 435 440 445

Glu Gly Glu Arg Pro Leu Thr Lys Asp Asn His Leu Leu Gly Thr Phe  
 450 455 460

Asp Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Val Pro Gln Ile Glu  
 465 470 475 480

Val Thr Phe Glu Ile Asp Val Asn Gly Ile Leu Arg Val Thr Ala Glu  
 485 490 495

Asp Lys Gly Thr Gly Asn Lys Asn Lys Ile Thr Ile Thr Asn Asp Gln  
 500 505 510

Asn Arg Leu Thr Pro Glu Glu Ile Glu Arg Met Val Asn Asp Ala Glu  
 515 520 525

Lys Phe Ala Glu Glu Asp Lys Lys Leu Lys Glu Arg Ile Asp Thr Arg  
 530 535 540

Asn Glu Leu Glu Ser Tyr Ala Tyr Ser Leu Lys Asn Gln Ile Gly Asp  
 545 550 555 560

Lys Glu Lys Leu Gly Gly Lys Leu Ser Ser Glu Asp Lys Glu Thr Met  
 565 570 575

Glu Lys Ala Val Glu Glu Lys Ile Glu Trp Leu Glu Ser His Gln Asp  
 580 585 590

Ala Asp Ile Glu Asp Phe Lys Ala Lys Lys Lys Glu Leu Glu Glu Ile  
 595 600 605

Val Gln Pro Ile Ile Ser Lys Leu Tyr Gly Ser Ala Gly Pro Pro Pro  
 610 615 620

Thr Gly Glu Glu Asp Thr Ala Glu Leu  
 625 630

<210> 3

<211> 1917

<212> DNA

<213> Homo sapiens

<400> 3

atggaggagg acaagaagga ggacgtgggc acggtggtcg gcatcgacct ggggaccacc 60  
 tactcctgcg tcggcgtgtt caagaacggc cgcgtggaga tcatcgccaa cgatcagggc 120  
 aacgcgatca cgccgtccta tgctgccttc actcctgaag gggaacgtct gattggcgat 180



```

gccgccaa accagctcac ctccaacccc gagaacacgg tctttgacgc caagcggtc 240
atcgccgca cgtggaatga cccgtctgtg cagcaggaca tcaagttctt gccgttcaag 300
gtggttgaaa agaaaactaa accatacatt caagttgata ttggaggtgg gcaaacaaag 360
acatttgctc ctgaagaat tcttgccatg gttctcacta aaatgaaaga aaccctgag 420
gcttatttgg gaaagaaggt taccatgca gttgttactg taccagccta ttttaatgat 480
gcccaacgcc aagcaaccaa agacgctgga actattgctg gcctaaatgt tatgaggatc 540
atcaacgagc ctacggcagc tgctattgct tatggcctgg ataagaggga gggggagaag 600
aacatctctg tgtttgacct ggttgccgga acctcgatg tgtctcttct caccattgac 660
aatggtgtct tcgaagtgtt ggcactaat ggagatactc atctgggtgg agaagacttt 720
gaccagcgtg tcattgaaaca cttcatcaaa ctgtacaaa agaagacggg caaagatgac 780
aggaaaagaca atagagctgt gcagaaactc cggcgcgagg tagaaaaggc caaacgggcc 840
ctgtcttctc agcatcaagc aagaattgaa attgagtcct tctatgaagg agaagacttt 900
tctgagaccc tgactcgggc caaatttgaa gagctcaaca tggatctgtt ccggtctact 960
atgaagcccg tccagaaagt gttggaagat tctgatttga agaagctctga tattgatgaa 1020
attgtctctg ttggtggctc gactcgaatt ccaaagattc agcaactggt taaagagttc 1080
ttcaatggca aggaaccatc ccgtggcata aaccagatg aagctgtagc gtatggtgct 1140
gctgtccagg ctggtgtgct cctcgtgtgat caagatacag gtgacctggg actgcttgat 1200
gtatgtcccc ttacacttgg tattgaaact gtgggaggtg tcatgaccaa actgattcca 1260
aggaacacag tgggtcctac caagaagtct cagatctttt ctacagcttc tgataatcaa 1320
ccaactgtta caatcaaggt ctatgaaggt gaaagacccc tgacaaaaga caatcatctt 1380
ctgggtacat ttgatctgac tggaaattcct cctgctcctc gtggggtccc acagattgaa 1440
gtcacctttg agatagatgt gaatggtatt cttcgagtga cagctgaaga caagggtaca 1500
gggaacaaaa ataagatcac aatcaccaat gaccagaatc gcctgacacc tgaagaaatc 1560
gaaaggatgg ttaatgatgc tgagaagttt gctgaggaag acaaaaagct caaggagcgc 1620
attgatacta gaaatgagtt ggaaagctat gcctattctc taaagaatca gattggagat 1680
aaagaaaagc tgggaggtaa actttctctc gaagataagg agaccatgga aaaagctgta 1740
gaagaaaaga ttgaatggct ggaagccac caagatgctg acattgaaga cttcaaagct 1800
aagaagaagg aactggaaga aattgttcaa ccaattatca gcaaactcta tggaagtgca 1860
ggccctcccc caactggtga agaggatata gcagaactcc accaccacca ccaccac 1917

```

<210> 4

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 4

tatacatatg gaggaggaca agaaggagga cg

32

<210> 5

<211> 32

<212> DNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:primer

&lt;400&gt; 5

ccacctcgag ttctgctgta tctctttcac ca

32